Cataflam

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Cataflam

What is Cataflam

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is used to reduce pain and inflammation. It works by blocking enzymes in the body that cause inflammation and pain. Diclofenac is often used as the first line of treatment for acute and chronic pain from a variety of sources. It is usually prescribed in combination with another drug, misoprostol, to prevent stomach ulcers caused by its use. Diclofenac was first approved by the FDA in 1988 and is sold under the brand name Voltaren.

Voltaren

is the brand name

image of different drug pills on a surface

Cataflam Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Cataflam Affects Patients

Diclofenac is used to reduce inflammation, pain, and fever. However, taking it can increase the risk of developing an ulcer in the stomach, since it reduces the amount of protective mucus produced.

How Cataflam works in the body

Diclofenac works by blocking enzymes that produce molecules called prostaglandins. Prostaglandins play a role in pain and inflammation. They make your body more sensitive to pain and reduce your immune response. Prostaglandins also widen your blood vessels, which can cause inflammation. By blocking these enzymes, the prostaglandins don't get made and inflammation can be reduced. In addition, diclofenac stops these molecules from triggering a fever.

When to interrupt dosage

The recommended amount of Cataflam is contingent upon the identified state, such as Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The dosage fluctuates in accordance with the technique of delivery (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) specified in the following table.

Condition

Dosage

Administration

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Cataract Surgery

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Postoperative Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Radiculopathy

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Acute Coryza

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

perioperative miosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

radial keratotomy

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Actinic Keratosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Arthralgia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Primary Dysmenorrhoea

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Patch, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical, Sublingual

Warnings

Cataflam Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Cataflam.

Common Cataflam Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Cataflam Toxicity & Overdose Risk

Overdosing on Voltaren can lead to symptoms such as tiredness, sleepiness, nausea, vomiting, and pain in the upper abdomen. In rare cases, patients may experience high blood pressure, kidney damage or failure, shallow breathing, or coma. Treatments for Voltaren overdose include inducing vomiting and activated charcoal, as long as the overdose occurred within the last 4 hours.

image of a doctor in a lab doing drug, clinical research

Cataflam Novel Uses: Which Conditions Have a Clinical Trial Featuring Cataflam?

491 active clinical trials are currently examining the potential of Cataflam to reduce Inflammation, facilitate Argon Laser Trabeculoplasty and ameliorate Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Inflammation

54 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4

Osteoarthritis of the Knee

75 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Chronic Pain

122 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Postoperative Pain

20 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

3 Actively Recruiting

Phase 4, Not Applicable, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

3 Actively Recruiting

Not Applicable

Pain

3 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

7 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Cataflam Reviews: What are patients saying about Cataflam?

5

Patient Review

10/10/2011

Cataflam for Painful Periods

Cataflam quickly and effectively alleviated the pain I was experiencing from my broken tooth.

5

Patient Review

3/4/2015

Cataflam for Pain

This really helped with my gum inflammation and tooth pain.

5

Patient Review

8/30/2017

Cataflam for Pain

I was in a lot of pain while on vacation, but this medication turned things around fast. I saw results after just two doses and felt better within 24 hours.

5

Patient Review

8/25/2012

Cataflam for Painful Periods

I'm not sure how effective this medication is because I take tramadol for pain relief.

5

Patient Review

6/10/2011

Cataflam for Pain

5

Patient Review

6/3/2022

Cataflam for Migraine Headache

This is my go-to treatment when I'm feeling stressed or have had too much wine. I drink it dissolved in a large glass of water and I'm good as new the next day.

4.7

Patient Review

9/15/2016

Cataflam for Pain

I have fibromyalgia and rheumatoid arthritis. I've been taking Ubuntu for years, and it works well for what it is. They changed my medication to this one because of severe headaches and dizziness, but it does not work! I hurt all over and am so tired - it's awful!

4

Patient Review

9/28/2013

Cataflam for Painful Periods

I was prescribed this to help with my endometriosis symptoms. The first pill did provide some relief, but after taking the second pill just a few hours later I felt incredibly nauseous. Not sure if the pain relief is worth the stomach upset.

3.7

Patient Review

10/27/2012

Cataflam for Migraine Headache

I've tried a lot of different medications for my chronic back and leg pain, and this one was just not effective at all.

3.3

Patient Review

8/17/2011

Cataflam for Rheumatoid Arthritis

The medication was prescribed to me for pain, but I only made it two days before having to stop. I developed intense stomach problems and weakness in my lower abdomen. After reading the side effects, I think this drug should be taken off the market. The negatives seem to outweigh any positives.

3.3

Patient Review

5/4/2013

Cataflam for Painful Periods

It would be helpful if there was a date on the article so readers know if the information is current. I stopped prescribing Cataflam because of the risk of heart attack.

3

Patient Review

6/29/2012

Cataflam for Pain

Even after taking both the cataflam 50mg and ibuprofen, my toothache pain has not subsided. I'm going to have to tough it out until I can see a dentist for a root canal.

2.7

Patient Review

4/28/2012

Cataflam for Pain

I've found this to be a little effective.

2.3

Patient Review

7/27/2012

Cataflam for Pain

Cataflam has been a saving grace for me. They provide much-needed relief when my condition gets bad and I can't leave home without them. Overall, they've really improved the quality of my life.

2.3

Patient Review

1/28/2011

Cataflam for Pain

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cataflam

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of painkiller is Cataflam?

"Cataflam is a drug used to treat pain or inflammation caused by arthritis or ankylosing spondylitis. It is a nonsteroidal anti-inflammatory drug (NSAID)."

Answered by AI

Do you need a prescription for Cataflam?

"Cataflam is a medication used to relieve mild to moderate pain caused by conditions such as arthritis, menstrual cramps, and migraines. It can be taken alone or with other medications and belongs to a class of drugs called NSAIDs."

Answered by AI

What is a Cataflam used for?

"This medication is an NSAID, which stands for nonsteroidal anti-inflammatory drug. NSAIDs are used to relieve pain, swelling, and stiffness caused by various conditions such as muscle aches, backaches, dental pain, menstrual cramps, sports injuries, and arthritis. Reducing symptoms with an NSAID allows people to more easily do their normal daily activities."

Answered by AI

Who should not take Cataflam?

"Meningitis that is not caused by an infection, systemic mastocytosis, dehydration, hepatic porphyria, anemia, increased risk of bleeding due to clotting disorder, an increased risk of bleeding, and alcoholism can all lead to problems with the nervous system."

Answered by AI

Clinical Trials for Cataflam

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Image of Montana State University in Bozeman, United States.

Haskap Berries for Exercise Performance Recovery

18 - 35
All Sexes
Bozeman, MT

The purpose of this clinical trial is to determine how certain food items affect oxidative stress, inflammation, and performance recovery from exercise induced muscle damage in a resistance trained population. The main questions The investigators aim to answer are the following: * Do Haskaps speed the recovery of oxidative stress and inflammation markers after an intense lower body workout in resistance trained adults? * Do Haskaps speed the recovery of performance measures after an intense lower body workout in resistance trained adults? * The data collected in this investigation may also be used to ask additional questions not yet identified. For example, the investigators may use the stored samples to evaluate how the blood metabolites of participants differ before and after intense exercise. These additional questions are called secondary analyses. Please note that no genetic analysis will be conducted and racial and ethnic differences among participants will not be used in any secondary analyses. Researches will compare Haskap juice to a color, flavor and carbohydrate matched placebo to see if Haskaps speed recovery in inflammation, oxidative stress and performance. * Participants will be asked to drink either Haskap juice or placebo and follow a low polyphenolic diet * Participants will perform an intense resistance workout * Participants will have their blood drawn before and after the workout * Performance will be analyzed at 24, 48 and 72 hours after the workout

Recruiting
Paid Trial

Montana State University

Mary P Miles

Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Pain Medicines for Period Pain in Crohn's Disease

18 - 44
Female
Chapel Hill, NC

The purpose of this pilot study is to prepare for a larger study that will compare the effectiveness and safety of two common pain medications, ibuprofen and acetaminophen, to help treat period cramps in women with Crohn's disease. The goal of this study is to identify any challenges in running a larger study. The investigators will track how many people sign up for the study, how well participants follow the study plan, how many people stay in the study, and whether they are able to complete all the study activities, such as taking the medication, submitting samples, and filling out surveys. During the study, participants will undergo a screening visit that includes a blood draw, physical exam, pregnancy test, stool testing, and complete surveys about Crohn's disease and menstrual cycles. Once this visit is complete, the rest of the study will occur at home. Participants will be assigned to take either ibuprofen or acetaminophen to help treat period cramps for four menstrual cycles in a row. Participants will take ibuprofen for two cycles and acetaminophen for two cycles. Participants will know which medication is being taken at any given time, but the order in which they take the medications will be randomly assigned. Before each menstrual cycle, participants will submit a stool sample and fill out a short (\<1 minute) electronic survey. When participants develop period cramps, they will take the assigned medication for three days and fill out short (\<1 minute) electronic surveys about their cramps. After participants finish taking the medication for three days, they will submit another stool sample and fill out two more short (\<1 minute) electronic surveys. After have completing this process for four menstrual cycles, a remote interview with a researcher to give feedback on the study will be conducted.

Waitlist Available
Has No Placebo

University of North Carolina at Chapel Hill

Erica J Brenner, MD, MSCR

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Have you considered Cataflam clinical trials?

We made a collection of clinical trials featuring Cataflam, we think they might fit your search criteria.
Go to Trials
Image of Byers Eye Institute in Palo Alto, United States.

LLM-Based Education for Cataract Surgery

18+
All Sexes
Palo Alto, CA

Patients with cataracts disease need to choose what type of artificial lens will go into their eye prior to surgery date. Some lenses are standard and are usually covered by insurance. Other "premium" lenses have various benefits such as reducing the need for glasses but usually require out-of-pocket costs. The combined busy outpatient clinic and complexity of artificial lens choices in the ever-changing world of cataract surgery tends to lead patients confused about their available lens options. There is an abundance of educational material present in premium lenses, however these are limited by accessibility and are standardized at single educational levels. Therefore in the present study, we want to test whether giving patients a short LLM powered AI-guided explanation from Custom GPT from OpenAI of lens options prior to their consultation with their doctor can improve visit efficiency, physician explanation and patient understanding of lens options. We will compare two groups: standard of care versus standard of care plus AI education. The LLM in this study is intended to provide supplemental information about premium intraocular lens(IOLs) options to study participants, and is no means supposed to replace a health care professional in the diagnosis, cure, treatment, and/or mitigation of disease. Study is analogous to giving a verified health pamphlet to a patient for them to view and learn different IOL options, in other words, facilitating patient understanding of their options. The LLM will be trained by several health care professionals and MD specialists to provide sufficient instructions. Sources will include verified online resources and MD information. The investigators hope to learn if a large language model-based educational tool can improve visit efficiency, physician explanation and patient understanding of intraocular lens options. New knowledge of this study could guide how cataract counseling is delivered in the future and may help clinics spend more time on individualized questions instead of repeating generic information.

Waitlist Available
Has No Placebo

Byers Eye Institute

Robert T Chang, MD

Image of University of New Brunswick in Fredericton, Canada.

Mediterranean Diet for Toddler Health

24 - 36
All Sexes
Fredericton, Canada

Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns. In this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites. This first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.

Waitlist Available
Has No Placebo

University of New Brunswick

Dr. Maryam Kebbe, PhD, CLC

Have you considered Cataflam clinical trials?

We made a collection of clinical trials featuring Cataflam, we think they might fit your search criteria.
Go to Trials

Have you considered Cataflam clinical trials?

We made a collection of clinical trials featuring Cataflam, we think they might fit your search criteria.
Go to Trials